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DISORDER 
ALEXANDER S. GUREGHIAN 
ABSTRACT 
Opioid use disorder (OUD) is a chronic relapsing condition associated with 
significant patient morbidity and mortality. Patients suffering from OUD have an 
increased risk of death from suicide, HIV, infectious disease, and trauma, among other 
causes. Patients suffering from OUD often manage various comorbid psychiatric illnesses 
and homelessness. From 1999 to 2017, an estimated 400,000 people died from 
prescription opioid related overdoses. In 2014, there were 28,647 opioid related overdose 
deaths in the United States. 
The current standard of care for treatment of OUD is an opioid receptor agonist 
methadone or buprenorphine combined with a psychosocial intervention, like cognitive 
behavioral therapy (CBT), contingency management (CM), or motivational interviewing 
(MI). MI has proven to be effective in treating OUD when combined with methadone and 
buprenorphine.  
Other studies have found increased rates of opioid abstinence when study subjects 
were provided recovery housing contingent on urine that was free of opioids and other 
substances (CM). Among patients with a history of incarceration and co-morbid OUD, 
stable housing in some form -- private residence or living with a friend or family -- has 
v 
been found to be effective in reducing opioid use when compared to homelessness as a 
control, suggesting homelessness confers a higher risk of opioid use. 
This prospective observational study aims to evaluate the effect of stable housing 
on opioid use disorder treatment and recovery. Study subjects will be Boston area 
residents who are prescribed methadone. Investigators will follow study subjects over six 
months while they attend weekly motivational interviewing sessions as part of their 
treatment regime and attend methadone clinics as usual. Once per week, study subjects 
will submit urine samples to study affiliated Medical Assistants (MA). Urine samples 
will be sent to LabCorp for toxicology analysis.  
At the conclusion of the study, investigators will examine which patients had 
longer time to relapse based on their housing status. We hypothesize that subjects with 
stable housing will have longer abstinence, as measured by urine toxicology, than 
subjects without stable housing. 
Positive findings could be used to help influence policy makers and federal and 
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Opioids are partial or fully synthetic analogues of naturally occurring opiate 
products derived from Papaver somniferum, commonly known as the opium poppy. 
Opium, codeine, and morphine are well known examples of opiates, while 
hydrocodone, hydromorphone and fentanyl are examples of partial or fully synthetic 
opioids.1,2  
Opioids are widely prescribed for pain, gut motility, and cough suppression. 
Opioids have been used globally for their analgesic, euphoric, and central nervous 
system (CNS) altering effects. Repeated or chronic opioid use induces changes in 
neuronal circuitry and can lead to a drug-dependent state.85 
Patients with opioid use disorder (OUD) often go through periods of 
successful abstinence.1 OUD is often characterized as a chronic, relapsing condition 
associated with high  patient morbidity and mortality.3 A 2016 review of OUD 
concluded that the risk of premature death from suicide, HIV, other infectious 
disease, trauma, or accidental overdose is 20-fold greater in patients with OUD.1
Opioid receptor modulators like naltrexone, methadone, and buprenorphine have been 
widely studied and are effective in the treatment of OUD.18 
Opium in some form has been used for chronic and acute pain for thousands 
of years.2 In 1806 the first opioid drugs were produced after isolation of morphine 
alkaloid. Opium use began in the 1800s as treatment for “travails” and “boredom”.2 




remedies at the time but particularly harmful if misused.87 After advocacy from 
Adams and like-minded physicians, a change in prescription practice occurred, 
leading to a more restrained approach to opioid use.87 
 Limited oversight prior to 1914 allowed physicians to freely prescribe opioids 
for pain, cough, anxiety, and diarrhea.86 In the early 1900s, use of opium or its 
derivatives and cocaine was rampant throughout the United States.88 The Harrison 
Anti-Narcotic Control Act of 1914 made writing prescriptions for opioids an ability 
limited to physicians, dentists, and veterinarians.6,88  In 1973, physicians at the 
National Institute of Health (NIH) described a “failure to treat” patients with severe 
pain with adequate opioid analgesics.6 A 1980 landmark study in the New England 
Journal of Medicine (NEJM) concluded that the development of addiction in 
hospitalized patients was rare in those with no addiction history.7 Later, a widely 
cited 1986 article in the journal Pain described treatment successes in cancer pain 
with opioid analgesics.8 
Later, ubiquitously prescribed extended release opioid agonist OxyContin was 
introduced and marketed to medical organizations, lawmakers, and physicians as non-
habit forming medication for pain control.9 Off-label use of the fentanyl lollipop, 
Actiq10, pharmaceutical kickback schemes with a fentanyl sublingual spray, Subsys11, 
and lucrative speaking and lobbying fees for physicians further contributed to the 
propagation of the opioid use epidemic in the 1990s and early 2000s.12,13 
In 2001, the Joint Commission called on providers to assess pain as “the fifth 




Framing pain within the vital sign structure drew attention to it and led to increased 
assessment by nursing and ancillary staff.14 In an attempt to eradicate pain, especially 
post-operative pain, some hospitals began to use sliding scales for administration of 
pain medications, including opioids.14  
 Today, OUD is a major public health issue. From 1999 to 2017, an estimated 
400,000 people died from overdose involving prescription opioid misuse.15 Deaths 
from drug overdoses nearly tripled from 1999-2014 (Figure 1.). Among 47,055 drug 
overdose deaths that occurred in 2014 in the United States, 28,647 (60.9%) involved 
an opioid.3 Prescription opioids remain a primary driver of opioid-related fatalities.4 
The rise of OUD is multifactorial. Opioid based approaches to pain control, limited 







Figure 1. Overdose Death Rates Involving Opioids by Type in the US 2000-2017. 
Obtained from CDC.gov, A graph of the rate of overdose death rates involving an 
opioid from 2000-2017. The graph separates incidence of death per opioid involved.  
   
The opioid use epidemic is separated into three stages.9 Stage one began in the 
late 1990s and early 2000s with a greater availability and distribution of OxyContin, 
extended release oxycodone. Patient privacy laws and lack of a formal prescription 
tracking structure made diversion possible.9 Stage two began in the early 2010s as 
updated prescription guidelines made obtaining OxyContin more difficult.9 Some 
patients switched to heroin because it was affordable and easier to obtain.9 Around 
2013, the opioid use paradigm shifted a third time. Illicit substance manufacturers 




(oxycodone-acetaminophen), and the benzodiazepine Xanax (alprazolam).104 
Fentanyl-laced marijuana has also been reported.103 Fentanyl is a cheap, fully 
synthetic opioid, 50 to 100 times more potent than morphine.38 Overdoses from 
fentanyl, heroin and combinations increased 88% per year from 2013-2016.9 Poverty 
and substance use disorders operate synergistically and can be reinforced by 
psychiatric disorders and social determinants of health like unstable housing.16 In 
2018, investigators at the U.S. Department of Health and Human services concluded 
that high rates of poverty and unemployment were associated with increased rates of 
retail opioids sales, utilization, prescription, opioid-related hospitalizations and drug 
overdose deaths.111 Additionally, investigators found that, among the counties studied, 
the ones with worse economic prospects had higher rates of opioid use and other 
substance use.111 Psychiatric and other substance use disorders (SUD) are highly 
comorbid with OUD. Kessler, et al, showed that 27% of patients with a DSM-IV 
diagnosis of OUD had at least one other psychiatric disorder. Among the 27% of 
patients with OUD and another psychiatric disorder, 45% of them had two or more.49 
In Massachusetts, overdose -- primarily from opioids -- is the leading cause of death 
among patients suffering from homelessness.53 
 
Statement of the Problem 
Opioid agonist therapies like methadone and buprenorphine in combination 
with psychosocial therapies are effective in the treatment of OUD.18 Despite effective 




from OUD experience periods of exacerbation and remission and are vulnerable to 
relapse.18 Often social, financial, psychological, and medical issues are intertwined 
when treating OUD.   
The majority of studies on the treatment of OUD have focused on opioid 
receptor based therapies like methadone and buprenorphine combined with 
psychosocial therapies. There have been minimal studies on the impacts of social 
determinants of health – specifically housing and societal integration in OUD. The 
rise in use of prescription opioid analgesics, ease of access to heroin, fentanyl, and the 




Stably housed patients receiving an opioid receptor agonist plus psychosocial 
therapy for OUD will remain abstinent for longer than unstably housed patients. 
 
Objectives and specific aims 
 This thesis proposes a prospective observational cohort study of patients with 
a DSM-V diagnosis of OUD receiving methadone maintenance therapy (MMT). 
Patients with OUD will be recruited from five methadone clinics in Boston and 
grouped based on their housing status. Patients will be categorized into four groups: 




unstably housed; initially unstably housed and transitioned to stably housed; and 
unstably housed throughout the study.  
The primary objective is to compare the ratio of abstinent patients at one-, 
three, and six-month time points between housing groups. The secondary objective 
will be to measure the mean time to relapse of opioid use between the housing 
groups. Another secondary objective is to compare relapse of use of other substances 
beside opioids. Each patient will receive their regular dose of methadone along with 
weekly one-hour motivational interviewing session (MI) with a social worker. 
Motivational interviewing, is a communication technique that--through empathetic, 
non-judgmental, and supportive language--addresses patient ambivalence towards 
addictive behavior.   
Clinical end points of the study will be relapse of opioid use. A secondary 
outcome will be use of substances other than opioids such as cocaine. Specifically, 
this study will determine whether: 
● Among patients receiving MMT and MI, there is a difference in frequency of relapse 
and time to relapse of opioids in the four housing groups. 
● Among patients receiving MMT and MI, patients with stable housing throughout the 
study have a lower incidence of and longer time to relapse than patients that are 






Opiate Use Epidemiology 
 
Opiate Use Disorder (OUD) is a global issue associated with staggering rates of 
mortality and morbidity and has impacted society globally and economic welfare.19,20 
OUD occurs in people from all educational and socioeconomic backgrounds.1 In 2013, 
prescription opioid misuse cost the United States $78.5 billion when factoring in health 
care costs, treatments, and criminal justice costs.21 Opioids, mainly synthetic opioids, 
other than methadone are currently the main driver of drug overdose deaths.1  
According to the U.S. Centers for Disease Control (CDC) opioid use has reached 
epidemic levels, which they define as an increase, often sudden, in the number of cases of 
a disease above what is normally expected in a particular area.23 
In 2017, 70,237 drug overdose deaths occurred in the U.S.15, 67.8% of which 
involved an opioid and 45.2% of which involved a synthetic opioid.15,24  
Drug overdose deaths involving natural and synthetic opioids, increased six-fold 
since 1999.24 There has been a dramatic rise in deaths as a result of synthetic opioids like 
fentanyl, and tramadol (Figure 1). In 2015, an estimated 5.1 million Americans had used 
heroin at some point in their lives.3 The age-adjusted rate of overall drug overdose deaths 
increased by 9.6% from 2016 (19.8 per 100,000) to 2017 (21.7 per 100,000).25 
In 2016, opioid related deaths were highest among people aged 25-34 (34.6 per 
100,000) (Figure 1) The rate of drug overdose deaths involving synthetic opioids other 




2015, and 6.2 in 2016.26 Synthetic opioid related overdose deaths increased an average of 
18% per year from 1999-2006, did not statistically change from 2006-2013, then 
increased markedly to 88% per year from 2013-2016.26 
 
Diagnosis of Opioid Use Disorder 
 Diagnosis of OUD is made clinically. Diagnostic criteria is made through the 
Diagnostic and Statistical Manual (DSM) of Mental Disorders and has been adopted by 
the American Society of Addiction Medicine (ASAM) and the CDC.  
Mild OUD is described as two or three behaviors out of eleven listed by the DSM 
as behavior concerning for OUD. Moderate and severe OUD follow with four to five 
behaviors, and more than six behaviors over a 12 month periods.  
 The complete list of DSM classified behaviors concerning for OUD can be found 
Appendix 1.  
 
Opiate Mechanism of Action 
Opioid receptors -- Mu, Kappa, and Delta -- are located throughout the central 
nervous system (CNS). They influence pain and pleasure perception, emotion, respiratory 
depression, and overall well-being.28 Mu, Kappa and Delta opioid receptors are coupled to 
G proteins. Upon binding of an opioid to Mu, Kappa, or Delta receptors, the associated G 
proteins trigger a signaling cascade, leading to feelings of euphoria, analgesia, and CNS 
depression.29 Opioids also bind to CNS dopamine, gamma-aminobutyric acid (GABA), and 




such as cyclic adenosine monophosphate (cAMP). Chronic opioid receptor activation leads 
to chronic upregulation of cAMP and changes in gene expression.29  
Chronic opioid receptor stimulation and upregulation of cAMP is thought to lead 
to the physical symptoms of withdrawal.30 Symptoms of withdrawal from opioids 
include1 diarrhea, dilated pupils, generalized pain, restlessness and anxiety, lacrimation, 
rhinorrhea, and pilo-erection. 
Clinical manifestations of opioid receptor activation depend on receptor location 
in the CNS. Frequency of activation and duration of activation play a role in clinical 
manifestations or withdrawal. Peripheral nervous system (PNS) Mu receptor activation in 
the bronchioles and intestines can lead to cough suppression and opiate induced 
constipation, respectively.29 Reward center activation and rapid delivery make opioids 
easily addictive.28  
Research into neural connectivity regulating addiction, binge/intoxication, 
cravings, and withdrawal reveals that the process of addiction involves overlapping 
networks. Positive reinforcement of the mesolimbic reward circuitry is thought to be 
responsible for learning associations between substance use and relief of undesirable 
states or situations.90  
 
Clinical Manifestations of Opiate Use Disorder 
Patients suffering from OUD present in a clinical spectrum depending on the 
length of dependence, severity and abstinence and include – acute intoxication, opioid 




speech, sedation with head nodding, miotic pupils, decreased respiratory rate, decreased 
tidal volume, decreased bowel sounds, and fresh injection sites.29 Opioid overdose 
requires emergency medical treatment.78 Severe opioid overdose is characterized by 
respiratory depression and requires emergency naloxone to reverse symptoms.31  
 Long-term opioid use can lead to rapid development of opioid analgesia 
tolerance.91 User tolerance to opioid induced nausea and respiratory depression develops 
slowly.91 Patients with opioid tolerance will require increased dosing to achieve desired 
analgesic and euphoric effects.1 Patients who resume opioid use from a period of 
abstinence have reduced tolerance and are prone to respiratory depression should they 
resume at a previously tolerated dose. 
Opioid use, misuse, abuse, and dependence are important distinctions.31 Opioid 
use encompasses use per prescription guidance, misuse, and use because of dependence. 
Misuse of opioids is defined as use beyond prescription guidance. Patients reporting 
misuse may obtain opioids from family members, seek opioids from multiple health care 
providers, and fill prescriptions from different pharmacies.110 Patients with opioid 
dependence go through withdrawal without the substance.  
Functional impairments develop with normal use or misuse of opioids.31 Patients 
with moderate to severe OUD may have impaired social functioning. Patients with DSM-
V diagnosed mild OUD are often able to maintain relationships and employment. Normal 
use of opioids may yield a diagnosis of mild OUD should the patient develop tolerance 




criteria for mild OUD requires just two points out of 11 so long as the patient displays a 
consistent pattern of use and functional impairment or distress over 12 months.   
  
Prescription Pain Medication Misuse 
In the 1990s extended release opioids, transdermal patches, nasal sprays, oral 
dissolving strips, and pain medication implant devices were developed and marketed, 
often illegally.16  
OxyContin was marketed to medical organizations, lawmakers, and physicians as 
a non-habit-forming medication for pain control.9  
Cephalon, the manufacturer of Actiq, an oral transmucosal fentanyl citrate10, 
trained its sales staff to promote Actiq for use beyond its FDA approval. Actiq was 
approved by the FDA for treatment of refractory pain for opioid tolerant patients.  
Despite warnings from the FDA, Cephalon marketed Actiq as pain control for opioid 
naïve patients.91 Cephalon paid a $425-million settlement to resolve the allegations in 
2008.91  
In 2012, Insys introduced Subsys, a sublingual fentanyl spray. Its FDA approval 
was for use in patients with persistent breakthrough pain, refractory to previous opioid 
therapy. From 2012 to 2015, Insys used speaker programs to raise brand awareness and 
provided lunches and dinners to practitioners prescribing Subsys. Insys paid kickbacks 
and bribes to increase prescriptions and dosages of Subsys.92 Insys agreed to pay $225 




Many patients with OUD were exposed to a prescription opioid like Actiq and 
Subsys prior to opioid misuse and seeking of ilicit opioids like heroin.35  From 2013 to 
2016, deaths from fentanyl and its analogs increased by 540% nationally.16 Since 2013, 
illicit fentanyl has been included in formulations of cocaine and counterfeit Norco, 
Percocet, Xanax, heroin, and even marijuana, with or without the user’s knowledge.37,38 
Fentanyl is 50 to 100 times38 more potent than morphine.38  
In the U.S., use of prescription opioids has been associated with a dramatic rise in 
overdose death and transition to other opiates and opioids.39  
 
Opiate Use in Pregnancy 
 Prenatal exposure to opioids increases the risk of preterm labor, stillbirth, 
neonatal abstinence syndrome, and maternal mortality.40 From 1999 to 2014, the 
prevalence of OUD among pregnant women increased from 1.5 to 6.5 cases per 1000 
delivery hospitalizations.40 This trend was found across all 50 states.40   
Loss of custody of their children, among other consequences imposed on pregnant 
women for opioid use, may prevent many from seeking OUD treatment and prenatal 
care.42  
Opioid detoxification in pregnancy is not recommended.42,43 Maternal detox prior 
to delivery of the newborn does not reduce the incidence of neonatal abstinence 
syndrome (NAS).105 Additionally, patients often relapse prior to the completion of 
detox105 with continued use of intravenous opioids potentiating the risk of infectious 




maintenance therapy (MMT), however, minimizes risky behavior, reduces transmission 
of infectious disease, and reduces withdrawal.44 The American College of Obstetricians 
and Gynecologists (ACOG) recommends methadone or buprenorphine as optimal 
treatments for OUD in pregnancy.105  
Prenatal exposure to opioids including methadone and buprenorphine increases 
the risk for neonatal abstinence syndrome (NAS).93 Infants with NAS are at risk for 
increased morbidity.93 Symptoms of NAS include high-pitched crying, irritability, 
exaggerated reflexes, tremors, seizures, vomiting, loose stools, poor feeding, constant 
sucking, failure to thrive, diaphoresis, sneezing, temperature instability, nasal stuffiness, 
and yawning.94 NAS screening should be completed on all infants exposed to pre-natal 
opioids every few hours until discharge.107  
Non-pharmacological approaches to treating NAS should be considered before 
pharmacological ones and should not be considered substitutes.107 A multidisciplinary 
team of psychiatrists, obstetricians, mid-wives, mental health therapists, pediatricians, 
nurses, and social workers is necessary for the optimal treatment of NAS.107 The goal of 
treatment in NAS is principally to reduce symptoms. Treatment of NAS begins with a 
non-pharmacological approach. For example, if the infant presents with tremors 
associated with NAS, positioning and swaddling should be considered to help the infant 
calm down. Non-pharmacological interventions for the treatment of NAS should be 
considered for short-term improvement of symptoms (Appendix 2).106 NAS symptoms 
may be scored using the Johns Hopkins NAS scoring form (Appendix 3).109 According to 




pharmacological interventions for NAS.106 Infants with severe NAS refractory to 
morphine or methadone may be started on clonidine or phenobarbital in addition to 
morphine or methadone.106 Clonidine is a reasonable alternative to phenobarbital due to 
the risk of sedation in phenobarbital. Naloxone should be avoided because it may 
precipitate rapid withdrawal. As the infant begins to improve clinically and exhibit fewer 
symptoms from the Johns Hopkins NAS scoring form (Appendix 3), drug therapy is 
weaned.107 
Risk Factors for OUD 
Chronic Pain 
Chronic pain often leads to anxiety, depression, problems with mobility, limits 
daily activity and reduces the quality of life.46 In 2016 the CDC estimated 50 million 
Americans suffer from chronic pain. More than 40% of older Americans deal with 
chronic pain and its sequelae.28 Opioid pain regimens for cancer related pain have 
increased over the past two decades.45 As many as 11.5 million people are prescribed 
long-term opioids for chronic pain.47 Balancing chronic pain while reducing the risk of 
opioid abuse, misuse, and diversion is critical in the prevention of OUD.45 
  
Co-morbid Opioid Use Disorder and Psychiatric Disorders 
 OUD and psychiatric disorders are often co-morbid but their relationship is not 
fully understood.48 The American Society of Addiction Medicine has hypothesized that 
there is a genetic vulnerability in the dysregulation of dopamine and glutamine in 




disorders.48 Opioids have also been seen as a way of self-medicating.48 SUDs and anxiety 
related disorders, such as post-traumatic stress disorder and obsessive compulsive 
disorder, commonly co-occur.49 Studies have found that prescription opioids can be used 
to cope with psychological and emotional discomfort and distress.50 A 2013 study in the 
American Journal of Addiction found that, among 85 patients with prescription opioid 
dependence, 47.1% were diagnosed with a co-morbid anxiety or mood disorder.51  
 
Housing 
 As many as 3.5 million Americans experience periods of homelessness 
annually.52 People experiencing homelessness have a higher prevalence of medical and 
psychiatric illness and substance use.53 A 2013 study in Boston found that opioid 
overdose was responsible for more than 80% of deaths among people suffering from 
homelessness. In the same study, unstably housed male patients aged 25 to 44 were nine 
times more likely to die of overdose than similar patients who had stable housing.53 
Neighborhood and social networking are contributing factors to substance use.54 
Economically disadvantaged neighborhoods are prone to disinvestment, abandonment, 
and crime. Inadequate living situations may lead to higher levels of psychological 
distress.54 Abandoned homes and buildings can be convenient locales for substance use 
behaviors and can be sanctuaries for other illicit behaviors. 54 Substance use abstinence 
has been shown to improve when people move to less economically disadvantaged 




naltrexone found that patients suffering from homelessness and co-morbid mental illness 
were less likely to adhere to naltrexone.55  
  
Opiate Use Disorder Treatment 
OUD treatment consists of both pharmacological and psychological approaches. 
Cognitive behavioral therapies (CBT) and motivational interviewing (MI) are methods of 
communication that foster healthier thinking and living. Longer treatment retention and 
MI is associated with greater likelihood of abstinence.  
Medication-assisted treatment combined with a psychosocial intervention is the 
most effective treatment option for OUD.56 Incarceration is negatively related to 
abstinence and is not a treatment on its own.19 
 
Medicinal Treatment Options for OUD 
According to the American Psychiatric Association, in patients with an extended 
history of opioid use, methadone or buprenorphine maintenance is appropriate.31 
 
Methadone 
Methadone (METHADOSE, DOLOPHINE) is a long-acting synthetic opioid 
receptor agonist. It is used to minimize opioid craving and withdrawal.18 A 2009 
Cochrane review found that methadone in conjunction with psychosocial therapy reduced 
opioid use, potential infection, and crime.57 Methadone maintenance programs have been 




decrease hepatitis infection, decrease crime, decrease illicit-substance use, improve social 
functioning, and increase the rate of retention to rehabilitation programs.1 Patients taking 
methadone were found to have reduced opioid use even without counseling services.58   
Conveniently, patients may receive methadone without risk of withdrawal. 
Additionally, methadone has been shown reduce psychiatric distress.48 Induction and 
stabilization of methadone begins with a 15-30mg oral dose. Dosage is increased by 10-
15mg every three to five days up to an average daily dose of 50-80mg. Dosing may be 
adjusted to minimize side effects and cravings, and optimize adherence.1 Methadone 
steady state should be at a level that avoids euphoria, sedation, prolonged QTc interval 
and opioid craving.1 Patients may remain on methadone for life. Tapering may be done, 
usually 5mg daily.31, however, a 2003 Cochrane review found that despite its efficacy in 
the prevention or minimization of opioid withdrawal symptoms, tapering methadone led 
to a majority of patients relapsing to heroin use.59 
A caveat to methadone treatment is that it currently must be dosed in specialized 
dispensing centers. At a methadone clinic, all patents must be evaluated by a physician to 
determine whether MMT is indicated. Providers should explain the rationale for MMT, 
the course of treatment, side effects, and other treatment options.60  
 
Buprenorphine 
Buprenorphine is a long-acting opioid partial agonist. It is available in a variety of 
forms -- oral sublingual (SUBOXONE, SUBUTEX), parenteral (BUPRENEX), patch 




Buprenorphine may be used once the patient is in mild-moderate withdrawal. Patients 
must be in mild to moderate acute withdrawal; otherwise buprenorphine will precipitate 
rapid withdrawal.18  
Use of buprenorphine to rapidly suppress opioid withdrawal is termed induction.95 
Failure to alleviate withdrawal symptoms may lead to the patient resuming use of 
opioids.95 Induction begins with a 4 to 8mg dose on day one, and up to 16mg daily on day 
two with dosing increases on subsequent days up to day seven.1 Dosage should be 
adjusted to minimize cravings and side effects.1  
 To avoid diversion, naloxone is added to buprenorphine to discourage injection. 
Naloxone, an opioid antagonist, will prevent feelings of euphoria should buprenorphine 
be crushed and injected in an opioid naïve patient. Injection of buprenorphine/naloxone 
in a patient with recent opioid receptor activation will trigger sudden, unpleasant 
withdrawal.62  
 Buprenorphine does not require a specialized clinic for distribution. 
Buprenorphine is a safer medication at induction than methadone because it does not 
carry the risk of QTc prolongation.1 Buprenorphine is prescribed only in medical offices, 
limiting access to patients with a primary care provider. Furthermore, federal law limits 
the number of patients a provider can “carry” in one year to 250. 
 
Naltrexone 
Naltrexone (VIVITROL, REVIA) is a long-acting mu receptor antagonist. 




motivated patients.1 Effects of subsequent opioid agonists are minimized or 
extinguished.18 Oral and intramuscular naltrexone (VIVITROL) has been found to be 
more effective than placebo in the treatment of OUD.64  
Patients should be abstinent from opioid agonists for at least 7 to 10 days prior to 
starting oral naltrexone or risk rapid withdrawal.96 Naltrexone induction and stabilization 
involves verifying opioid use status by an opioid negative urine sample. Upon opioid 
negative urine, a low dose oral naltrexone challenge may be administered. After 24 hours 
without withdrawal, intramuscular VIVITROL may be given.1 Similar to methadone and 
buprenorphine, patients taking naltrexone should receive psychosocial therapy.  
 Studies of OUD patient adherence to oral naltrexone have found that 50% of 
patients discontinue it in six weeks and 15% continue after 25 weeks.63 Naltrexone 
adherence is notoriously low, worse than methadone and buprenorphine. Thus, due to 
these issues in adherence, naltrexone is primarily a second-line strategy.31 Non-
adherences is dangerous because of the risk of loss of opioid tolerance while on 
naltrexone and subsequent overdose.98 
 
Psychological Treatment Options 
Cognitive Behavioral Therapy (CBT) 
CBT can help a patient identify distorted, maladaptive beliefs.17 CBT uses 
thought exercises, relaxation techniques, and stress exercises or real experiences to 
facilitate symptom reduction and improve patient functioning. Patients may improve 




CBT has been found to be effective for a variety of psychiatric disorders, including 
substance abuse, generalized anxiety, depression, panic disorder, and posttraumatic stress 
disorder. CBT for substance use disorder has been found to be effective as monotherapy 
and in combination therapy with social and family support.65 However, CBT alone did 
not improve abstinence rates for primary heroin users.66  
 
Contingency Management (CM) 
CM is a behavioral therapy where individuals are reinforced or rewarded for 
evidence of a positive behavioral change.67 Reinforcement of positive behavior will 
promote further good behavior, in this case, abstinence. CM has been found to improve 
opioid abstinence71 and medication compliance.72 Multiple studies have found CM to be 
effective in reducing stimulant misuse.68,69 Interestingly, CM was effective in patients 
receiving MMT.69 Meta-analyses of clinical trials in patients with varied SUDs have 
found CM to increase rates of drug abstinence during treatment compared to control 
interventions.70 However, 6 to 12 months after treatment the effects of CM were found to 
have not been sustained.70 In a clinical trial of 116 patients with OUD receiving 
methadone, those receiving CM were found to have greater percentage of opioid and 
cocaine free urine over the course of the study.73 
 
Motivational Interviewing 
 While patients experience euphoria while taking a substance, ambivalence follows 




substances. MI is a communication style that guides patients in resolving this 
ambivalence. Patients are encouraged to make changes to their lives through enhancing 
inner motivation.74 MI uses empathetic, nonjudgmental, and supportive approaches to 
address patient ambivalence towards addictive behavior. MI has been found to reduce 
DSM-IV diagnosed SUD.75 
 In 2005, investigators at Boston University Medical Center (BUMC) investigated 
the effects of brief MI on substance use in an emergency department (ED) population.76 
At the conclusion of the study, 40.2% of follow up patients (82% follow up rate) were 
abstinent from heroin after six months. Within the group that did not receive MI, only 
30.6% were abstinent from heroin. Similarly, 22.3% of the intervention group was 
abstinent from cocaine after six months compared to 16.9% within the group that did not 
receive MI (aOR = 1.51-1.57).76  
 Providers should help build awareness, support the patient in self-discovery, in 
their values and goals, and support the changes that the patient is ready for. Providers 
should be aware of patient readiness for change. Readiness for change is separated into 
six nonlinear stages: pre-contemplation, contemplation, preparation, action, maintenance, 
and relapse.31   
Motivational interviewing was built on four key tenets, highlighted in appendix 
477. In summary, providers should aim for collaboration with the patient, to be 
compassionate in understanding patient feelings, promote patient autonomy, and to evoke 
patient ideas rather than to assert opinions. A provider’s ability to use MI relies on four 




elaboration and consideration. They should positively affirm patient feelings and actively 
reflect on patient feelings to ensure to the patient that they are heard. Lastly, providers 
should summarize patient concerns and foster an environment of progress and build an 
interest in changing behavior.77 
 
Self-Help Groups 
In a longitudinal prospective cohort study of 142 opioid dependent patients 
attending Narcotics Anonymous (NA) and Alcoholics Anonymous (AA) found improved 
abstinence rates at five-year follow-up.78 Pre-treatment opioid abstinence was 19% and 
was 47% at five-year follow-up (p<0.001). Attendees were more likely to be abstinent to 
both opiates and alcohol than non-attenders of NA and AA.78  
 
Programs: 
In 1995, Boston Medical Center (BMC) created Project ASSERT, an ED-based 
program aiming to connect substance dependent patients to primary care providers and 
preventative medicine programs.85  
The original study by Bernstein et al screened 7,118 ED patents for illicit 
substance use. Substance use was detected among 41% (2931) of patients and 37% 
(1,096) of patients with a positive substance screen enrolled in Project ASSERT. Health 
promotion advocates screened patients on their readiness to change. Patients were given 
the opportunity to be referred to a substance use treatment program.80 Among the 




substance use programs, 2,253 for smoking cessation, 339 for mammography, and 689 
for psychiatry, social work, or for housing assistance.80 Some patients had multiple 
referrals made. Among 245 follow-up patients, there was a 45% reduction in severity of 
drug use and 56% reduction in alcohol use. Project ASSERT has been adopted in various 
EDs across America as a way to improve access to healthcare in the substance use 
population.80  
Project ASSERT continues to facilitate connections to support programs and 
mitigate social determinants of health. Its health promotion advocates have offered 
60,000 referrals to alcohol and drug screening and treatment programs since 1994.99 
Project ASSERT is an invaluable resource in connecting patients with SUDs to primary 
care, health and social services, assisting in obtaining health insurance, transportation, 
and temporary housing.  
Faster Paths to Treatment is a substance use urgent care center started in 2016 at 
BMC. Faster Paths provides referrals to addiction treatment, overdose education, Narcan, 
substance use counseling, MMT, buprenorphine, and referrals to primary care doctors at 
BMC.81  
BMC’s office-based addiction treatment (OBAT) program was created in 2003 to 
address the lack of clinical support for doctors in addiction medicine and addiction 
psychiatry.82 At OBAT, registered nurses minimize the barrier to receive buprenorphine 
by seeing substance use patients. OBAT has expanded patient access to healthcare 




A 2018 12-year retrospective study within BMC’s OBAT program investigated 
the effectiveness of a voluntary buprenorphine taper.82 Primary outcomes were 
completion of a buprenorphine taper. Secondary outcomes were re-engagement of care 
and resumed buprenorphine treatment after the voluntary taper. Among 1,308 OBAT 
patients, 48 attempted the buprenorphine taper (22 were medically supervised tapers) and 
13 patients resumed buprenorphine maintenance therapy.82 35 completed the taper. A 
2014 study in the Journal of the American Medical Association (JAMA) investigated the 
effectiveness of a buprenorphine taper in 113 patients over 14 weeks. Patients were 
randomized to a three-week buprenorphine taper after six-weeks of buprenorphine 
stabilization. Investigators found the buprenorphine taper much less efficacious in 
maintenance of opioid abstinence than continued use of buprenorphine.108 
 
Existing Research 
Review of the Standard of Care in the Treatment of OUD 
A 2016 systematic review by Dugosh et al in the Journal of Addiction Medicine 
investigated the use of various psychosocial interventions with buprenorphine or MMT in 
the treatment of OUD.18 Dugosh et al reviewed the standard of care for OUD. They aimed 
to find the optimal psychosocial intervention in achieving the highest rates of abstinence 
combined with either methadone or buprenorphine. They reviewed CBT, 12-step 
programs, MI, family therapy, group and individual counseling, and social skills training. 




therapeutic elements. Therapies aimed to modify underlying addictive behavior, 
encourage the use of pharmacotherapy, and treat psychiatric co-morbidities.  
 Reviewers followed the PRISMA guidelines.100 Reviewed journal articles were 
found through PubMed and PsycINFO databases. Reviewers broadened search terms to 
include all articles that described experimental trials investigating the efficacy of 
pharmacotherapy plus any psychosocial treatment for OUD. Search terms included 
special populations like pregnant women and adolescents. Editorials, commentaries, and 
overlapping articles were excluded.  
 1128 studies were reviewed; 190 duplicates were removed. Studies were excluded 
if they included non-human (5), editorials/obituaries/commentaries (N=32), Non-MAT + 
Psychosocial related (N=348), Not RCT (N=461), small sample size (N=3), Lacked 
control/comparison group (N=9), already updated articles (N=8), and not opioid-
treatment focused (N=45).  
 At the conclusion of the study, investigators found significant gaps in research 
still existed in quality of data, and special populations. The majority of studies examined 
psychosocial therapy plus methadone treatment. Buprenorphine was studied less. There 
was little empirical evidence to favor one psychosocial therapy over another when 
combined with methadone/buprenorphine. There were few comparison studies of 
psychosocial therapies for OUD treatment effectiveness. 
 Investigators examined two studies that compared CBT and methadone 
maintenance therapy to MMT alone in the treatment of OUD. Kouimtsidis et al compared 




the CBT group received 50 minutes of weekly counseling for the six-month study period. 
Investigators found no significant difference in the number of days abstinent, heroin use, 
psychosocial problem severity, quality of life, or MMT compliance.101 Moore et al 
randomized patients into MMT only or a phone-line based voice interactive system using 
CBT. In their four-week study, the two groups experienced no difference in self-reported 
substance use and urinalysis-verified opioid and cocaine use. 
 Nyamathi et al investigated MI when combined with MMT for patients with 
OUD. The study was broken down into three subgroups: one on one MI, MI in a group, 
and a nursing-led hepatitis health promotion group. There was no significant difference 
among the three groups in drug use during the intervention phase. At the six-month 
follow-up, patients receiving individual MI and group MI reported less substance use. A 
major caveat in the study was that substance use was self-reported. There was no follow-
up data after six months.  
 Dugosh and authors reviewed four studies that utilized CM as part of their 
treatment regimen for OUD. Two of the four CM studies were performed in China, the 
other two were performed in the United States. In each of the studies, prizes were 
awarded to patients who produced morphine negative urine samples biweekly over 12 
weeks. All patients received MMT and were encouraged to abstain from morphine if they 
produce a morphine-positive urine sample. The MMT+CM group consistently 
outperformed the MMT-only group. They were abstinent longer and had a greater 
number of overall opioid-free urine samples. This study was conducted in China and thus 




receiving CM provided more morphine-free urine samples than the group receiving 
methadone maintenance.   
 Another weakness of the study is that it is a systematic review, thus each of the 
populations that individual investigators draw on is different. A few of the examined 
control groups did not include methadone or buprenorphine only groups. The major 
weakness in the study is that none of the studies compared one type of psychosocial 
therapy to another one. In order to get an idea of the optimal psychosocial therapy for 
OUD, psychosocial therapies must be compared across diverse groups. Furthermore, 
among the studies examined in this systematic review, none were examined for weakness 
or bias.  
 Given Dugosh and authors' findings, there is significant work remaining as to the 
comparative effectiveness of one psychosocial therapy over another. Insufficient work 
has been done to assess the effectiveness of one psychosocial therapy over another. Given 
the litany of psychosocial therapies available for the treatment of OUD, differentiating 
one therapy versus another is essential to finding the optimal treatment regimen for OUD. 
Additionally, work should be done to elucidate whether buprenorphine or methadone is 
more effective given the patient’s situation and optimal psychosocial therapy. Dugosh’s 
chosen literature reviews did not mention any studies that looked particularly at substance 
abuse co-morbid with psychiatric illness. The effect of homelessness and psychiatric 





Generally, Dugosh et al found that MMT in combination with a non-specific 
psychosocial intervention to be effective in treating OUD. Nine out of 14 studies found 
improvement in treatment retention and opioid use. Five out of 14 found improvements in 
opioid use only. 
Housing in the treatment of OUD 
 Tuten et al in 201283 conducted a randomized prospective control trial studying 
the effect of abstinent contingent recovery housing (RH) plus abstinence reinforcement-
based therapy (RBT), RH alone, or usual care (UC) on opioid abstinence times.83  
The study screened 801 patients and investigators were able to recruit 243 opioid 
abstinent patients in Baltimore who received medical services from Johns Hopkins 
Bayview Medical campus. Patients were diagnosed with OUD by the DSM-IV criteria 
and were appropriately detoxed at the time of initiation of the study. Patients with 
psychiatric illness, pregnant patients and those receiving opioid agonist therapy and 
pregnancy were excluded. The primary outcomes of the study were opioid and cocaine 
use or abstinence at one-, three-, and six-month follow-ups measured in ratios.  
 The UC group was referred to substance use treatment programs and community 
resources alone. The RH group were provided drug-free housing, contingent on biweekly 
negative urine specimens in addition to UC. The study paid patients $105 a week for up 
to 12 weeks. Patients were required to submit urine samples biweekly. A positive 
urinalysis for cocaine or heroin was a primary endpoint. Upon submitting a cocaine or 
opioid positive urine sample, patients were removed from recovery housing and placed 




therapists once the patient submitted substance negative urine samples. The RBT+RH 
group received transportation to and from therapy for the course of the study. RBT+RH 
was based on community reinforcement therapy and also included CBT, recreational 
activities, vocational assistance, and intense individual counseling. Patients received daily 
treatment for the first three weeks and treatment four days per week for weeks four 
through 12.  
Post-hoc comparisons of the data found each of the treatment conditions varied at 
the one- and three-month time points. The outcome did not change as a result of the 
varying treatment conditions. The RBT+RH group was significantly more likely than the 
UC group to abstain from opioid and cocaine use at six months. In the RBT+RH group, 
37% abstained at six months versus 20% in the UC group (p<0.016).  RH+RBT groups 
were 10 times more likely than the UC group to abstain from opioids at each time point 
(25.9% versus 2.5%; p<0.001). The UC group was significantly more likely to be non-
abstinent at any time point. The UC and RH groups, as well as UC and RH+RBT groups, 
were significantly different as a result the addition of housing (p<0.001 for both) but 
RBT+RH and RH groups did not differ in abstinence times. Of note, the patients in the 
RBT+RH group had longer stays in recovery housing than the RH patients, 49.5 days for 
RBT+RH compared to 32.2 days for RH alone (p<0.002). 
Tuten et al reported their data at one and three months as a ratio, limiting analysis 
at these times. For abstinence at one and three months, data was extrapolated from an 




of RH, and about 5% of UC patients were abstinent. At three months, about 55% of 
RH+RBT patients, 40% of RH patients, and 15% of UC patients were abstinent.  
Tuten et al investigated psychosocial therapy in combination with stable housing 
in the treatment of OUD in patients that have completed medication assisted 
detoxification. Patients psychiatric illness, those who were pregnant, and those prescribed 
opioid agonists were excluded. The exclusion criteria made about 500 patients from the 
original screened population ineligible for the study. Furthermore, by excluding the 
patients taking opioid agonist medication including methadone and buprenorphine, the 
study is not taking into account the many patients that stay on methadone or 
buprenorphine and suffer from homelessness. The patients suffering from comorbid 
psychiatric conditions and patients taking methadone and buprenorphine while recovery 
from OUD would have been of particular interest to study. The exclusion of patients with 
co-morbid psychiatric illness is a major limitation given that psychiatric illness and 
substance use are often co-morbid.  
There was an incentive to be abstinent from opioids and cocaine given that 
recovery housing was contingent on opioid and cocaine free urine. Patients were placed 
in alternative housing upon an opioid or cocaine positive urine. Tuten and authors never 
disclosed the details of the alternative housing. There were no adverse outcomes 
described except the act of physically moving. If housing were not contingent on opioid 
negative urine samples, it is unclear how effective the psychosocial intervention would 
be. Treatment conditions varied at the one- and three-month time point but the 




abstinence time for RBT, RH or UC groups were not provided. In the analysis portion of 
the work by Tuten et al, they declined to include values for abstinence at one and three 
months. The data did not include a standard deviation or effect size between any of the 
groups.  
Tuten and authors concluded after analysis of their data that abstinent-contingent 
recovery housing improves abstinence in patients suffering from OUD following a 
medication assist detoxification. They found patients benefited from the reinforcement 
based behavioral counseling. Lastly, they found behavioral counselling improves patient 
outcomes by lengthening recovery housing stays.  
Housing stability as a part of Treatment of OUD 
Wooditch et al84 conducted a randomized retrospective clinical trial on residential 
mobility, housing stability, opioid and alcohol use in 504 patients with OUD for the prior 
30 days in Washington D.C. Each patient had a history of criminal justice involvement. 
The 504 patients were screened for OUD prior to the study.  
To be included in the study, patients had to be older than 18, able to provide 
informed consent, able to understand English, have medical entitlements in Washington, 
DC, and at the beginning of the study be abstinent from opioid medications for chronic 
pain and Suboxone. Patients were 51.7 years old on average, 98% African American, 
78% male, 73% unmarried, and 52% were on parole or awaiting trial.   
Of interest to this study, investigators found that living in shelters and halfway 
houses was associated with a decreased frequency of substance use. The investigators 




associated with a lower likelihood of substance use. These findings suggest that a 
structured living environment may influence behavior and reduce OUD. 
 Patients self-reported risky behavior, crime, treatment, housing status and 
incarceration. Patients were categorized into specific housing groups based on where they 
had spent at least 15 days over the 30-day study. Regression modeling was used to 
examine illicit substance use days. Living in regulated transitional housing (shelters or 
halfway homes) were related to fewer days of illicit substance use (B = -0.105, P<0.05). 
Patients in correctional facilities or drug treatment programs had fewer substance use 
days (B = -0.774; p <0.001). The residential transitions (B = -0.094) and days of 
homelessness (B = 0.100) were not associated with decreased substance use.   
 Wooditch and authors concluded that stable housing and its associated structure is 
an essential resource when treating motivated patients with OUD. Of note, patients on 
methadone/buprenorphine were excluded from the study, thus, highlighting the 
effectiveness of stable housing alone in treating OUD.  
Wooditch and authors were very selective in their inclusion criteria. They 
included only English-speaking patients over 18 years old with criminal backgrounds. 
The patient population was 98% African American which makes this study not as 
generalizable to the broader population. Housing group categorization was based on the 
location at which patients stayed for more than 15 days of the study 30 days is a 
relatively short time to see a robust effect. Patients had up on average 23.2 (SD = 12.8 
years) years of non-continuous heroin use. Prior to the study, the patients had, on 




Investigators reported modest positive data for incarcerated patients and study 
subjects living in halfway homes. Since this study was retrospectively done, patients that 
were lost to overdose were not included in this study. Retrospective studies introduce 
significant bias into the study because selection criteria can be manipulated to include 
patients with positive outcomes.  
Patients receiving more than 30mg of methadone or buprenorphine per day were 
excluded, limiting patients to those that are taking just <30mg methadone or 
buprenorphine excludes many subjects. Regarding data on patients that were actively 
incarcerated at the time, it stands to reason that the supply of substances is sparse in a 
prison or jail, a barrier to use. Secondly, there are patrolmen and guards presumably 
surveilling for any substance use behavior which is another barrier to use. However, this 
study’s most robust data comes from jails where opioid access is limited and where 
prison guards are on surveillance for substance use.  
Summary of Literature Review 
 Dugosh et al showed MI to be an effective psychosocial intervention when 
combined with methadone and buprenorphine as treatment for OUD. Tuten et al, showed 
that patients with OUD when given stable housing had improved abstinence rates at six 
months. Patients showed improved rate of abstinence when provided psychosocial 
therapy in combination with stable housing. Wooditch et al showed stable housing in 
some form whether it being half-way homes or jails/prisons were associated with fewer 
opioid use days. Each of the studies individually have shown positive outcomes to a 




effects of stable housing on the standard of care – psychosocial therapies plus methadone 







 Investigators will conduct a prospective cohort study of patients receiving 
methadone enrolled in a MMT clinic for OUD. We hypothesize that patients with greater 
housing stability will be more likely to be abstinent at one-, three- and six- months and 
have a smaller number of relapses and longer time to relapse than patients with less 
housing stability.  
Project Population and Sampling  
Investigators will recruit study subjects at methadone clinics in the city of Boston 
over a six-month period.  
A 2005 study by Bernstein and authors at BMC profiled racial and ethnic 
diversity among heroin and cocaine users by system utilization in Boston.114 
Conveniently, the proposed study population will be drawing from the same city albeit 
two decades apart. In 2005 the survey population was 61.7% Black, 23.1% Hispanic, 
14.1% White, and 1.1% Other. Blacks were 67.6% male, and 32.4% female. Hispanics 
were 82.4% male, and 17.7% female. Whites were 66.7% male, 33.3% female. 
According to the 2019 state census, Bostonians identifying as “White” alone not 
Hispanic, “Black”, “Asian”, “Hispanic or Latino”, and “more than one race” represented 
44.5%, 25.3%, 9.6% 19.7% and 5.1% respectively.112   
 Study subjects will be assumed to have a diagnosis OUD based on status as a 




A study affiliated BU employed medical assistant will be present at each 
methadone clinic for three months to complete OUD secondary screening. Secondary 
screening will cover days of opioid dependence, methadone use history and dosage and 
opioid dependence time frame. The medical assistants will be present for an additional 
six months during the study to collect urine samples. 
The sample size of the proposed study will be calculated with UCSF sample size 
calculator and based on work done by Tuten et al, who studied a population of 243 
patients, separated into three housing groups: 80 in recovery housing (RH) + 
reinforcement based training (RBT), 83 in RH only, and 80 in usual care (UC). A total of 
163 patients were exposed to housing in the study. The Tuten study was designed to 
include 67% of patients in the exposed group, RH+RBT and 33% of patients in the UC 
group. Thus, 67% and 33% (q1 = 0.670, q0 = 0.330) represent the proportions in the 
sample size calculations. Alpha level will be adjusted from 0.05 to 0.0127 using the 
Bonferroni because of multiple comparisons and beta level 0.80. Tuten and authors 
concluded at six months, that only 20% of UC patients remained abstinent. In contrast, 
the over six months, RH+RBT housing group was 37% abstinent (OR = 2.349, RR = 
1.850).  
To account for drop out, investigators will attempt to recruit 447 total patients 
with a minimum of 385 patients overall. Recruitment numbers adjustments were based on 
a 2000 randomized control trial by Sees and Authors.113 Sees and authors compared 
treatment outcomes in patients receiving MMT or psychosocial therapy over six months 




over six months. The study will need 300 housed patients to account for drop out with a 
minimum of 258 and 148 unhoused patients with a minimum of 127.  Significant patient 
dropout is common in prospective cohort studies. Total number of patients approached, 
recruited, and drop out will be recorded. 
Treatment, Intervention or Exposure Groups 
All patients will receive identical treatments: MMT dosed as usual per individual 
patient methadone maintenance regime and weekly one-hour MI with a social worker 
trained at least the bachelor’s level. Prior to the study beginning, each social worker will 
be trained on the nuances of motivational interviewing by a study affiliated psychiatrist, 
nurse practioner, or physician assistant. Social workers will be taught to use non-
judgmental, empathetic and supportive language to address any ambivalence towards 
abstinence.   
Patients will be asked about opioid use in the previous week by social workers 
while completing their weekly MI sessions. In addition, social workers will reinforce pro-
abstinence and pro-stable housing thoughts.  
Patients will receive a $25 Visa ClinCard for initial screening and for each 
subsequent MI therapy session as compensation for the subject’s time and transportation 
to and from methadone clinics.  
The study will aim to determine if there is a significant difference in the 
frequency of abstinence and time to abstinence between patients who are primarily living 
in stable housing and those in unstable housing. Patients will be grouped at the 




Patients will be separated into stably housed throughout the study, stably housed initially 
and then unstably housed, unstably housed then stably housed, and unstably housed 
throughout the study. Patients will be considered stably housed group if they are living in 
a place where they are named on the title or lease of the residence or if they live with 
family or friends. Patients living in halfway homes, shelters, abandoned buildings, or 
suffering from homelessness will be considered unstably housed. 
Project Variables and Measurement Tools 
An intake survey completed by the medical assistant (MA) at initial recruitment 
will determine age, sex, race, employment status, housing status, education level. Patients 
may make multiple changes in housing status over the course of the study. In the event of 
multiple housing transitions, the patient will be reclassified into the group where they 
spent the most time over the course of the study. 
The MA will complete an OUD screening survey with the study subject including 
the following: days of opioid use in the past 30 days, days of opioid dependence, 
methadone use history, methadone dosage, take-home status, opioid dependence time 
frame, and prescription drugs the patient is taking. These variables are important to 
define the baseline treatment characteristics of the cohort. 
This study will principally investigate frequency of abstinence and time to relapse 
for patients receiving MMT and MI with variable shelter status over six months. Patients 
will submit weekly urine samples for toxicology screening. The urine samples will be 
collected by an MA and sent out to LabCorp for expanded urine toxicology, including 




oxycodone, and THC. Patients will be asked about their substance use and housing status 
by a social worker during weekly MI sessions. An expanded urine substance panel was 
chosen as it helps us characterize the patient substance use patterns. The study design 
includes patients suffering from psychiatric comorbidities, these patients may be taking 
benzodiazepines or other substances as part of their treatment regime. These patient will 
be included for analysis of opioid use but the patients will not be counted as relapsed, if 
the patient uses a medication as prescribed.  
Recruitment 
MAs will approach patients presenting to five methadone clinics in the city of 
Boston for three months Monday through Friday in an attempt to recruit patients to the 
study. These patients will be regular patients of the methadone clinic. Additionally, 
patients will be recruited via referrals from primary care providers. Flyers will be posted 
throughout Boston to assist in recruiting.  
Participants in the proposed study will include minors, adults, patients with 
psychiatric comorbidities, homeless, and pregnant patients. Patients taking opioid pain 
medication will be excluded. Patients will be included regardless of their length of opioid 
abstinence. Patients receiving take home methadone will be included. 
Under BUMC IRB guidelines, investigators must obtain parent or guardian 
permission for subjects under the age of 18 to be able to participate. The proposed 
experiment must either be directly beneficial to the subject or be of minimal risk.  
MAs will follow a recruitment script based on and approved by the BUMC IRB 




all prospective patients. Questions will be answered by study staff. Participants will 
complete an informed consent to participate in the study and will receive a copy of the 
consent form. Once consented, participants will complete a brief paper survey on their 
age, race, employment and housing status, educational level, and perceived social 
barriers. Screening guidelines will follow approved BUMC screening guidelines.  
Upon completion of recruitment screening, the patients will be compensated with 
pre-card $25 Visa ClinCard. All study personnel will maintain privacy per HIPAA 
guidelines. Patient information access will be password protected and encoded for 
additional protection of sensitive information.    
Data Collection, and Data Safety and Monitoring 
 All data collection will be completed on paper and transferred to electronic patient 
logs. Subjective opioid use screening will be documented in electronic patient files by 
social workers. LabCorp urine toxicity will be accessed via LabCorp servers and 
uploaded to electronic patient logs. All physical documentation of patient information 
will be destroyed at the conclusion of the study. Electronic records of study data will be 
saved for seven years per BU and BUMC policy and encoded for patient privacy and 
protection. 
Analysis 
 Patient housing status will be determined at the conclusion of the study. The 
primary outcome of the study is to determine the ratio of relapsed patients at the one-, 
three-, and six- month time points. Due to the primary outcome of the Tuten and authors 




analysis for the time to relapse will be compared using Chi-square assuming parametric 
data. The Fisher exact test will be used if there are less than five variables in the 
contingency tables. 
The secondary outcome of the study will be to determine the difference in mean 
relapse time between the housing groups. Assuming normal distribution of data, the mean 
time to relapse of opioid use per housing group with standard deviation will be calculated 
and compared using one way-ANOVA analysis. If the distribution of frequency of 
relapse and time to relapse is not normal, a Kruskill-Wallace analysis will be attempted. 
If a difference in the relapse times between housing groups is found, then we will proceed 
with further testing to compare the difference between groups. This is a prospective 
cohort study with independent patients, thus frequency of relapse and time to relapse will 
be compared in an non-pair wise fashion using an unpaired t-test assuming a normal 
distribution. The Mann-Whitney U test will be used should the data prove not parametric. 
Another secondary outcome of the study will be an analysis of the frequency of 
relapse for other substances included in the expanded urine toxicology screening. To 
compare whether there is an overall difference in the populations, ANOVA will be used. 
The non-parametric analogue used would be the Kruskal-Wallis test. If there is a 
difference in the relapse rate of substances in the expanded urine toxicology screen, each 
population will be compared to the control using the unpaired T test if parametric, and 
Mann-Whitney U Test if non-parametric.   
Similarly, investigators will assess for frequency of relapse and time to relapse in 




The population data collected at the initial screening of the study subjects will be 
used to further analyze patients. For example, time to relapse for patients that marked 
living with family can be compared to the homeless population. Another example could 
be comparing time to relapse in patients with a greater than ten years’ history of 
intermittent opioid use compared to those who have started within the last year. 
Demographics will allow for further analysis of the population rather than simply 
between housed and homeless. For analysis of one subpopulation versus another, 
investigators may use an unpaired t-test if the data be regularly distributed. If the data is 
not regularly distributed, investigators may use the Mann-Whitney U Test.  
If patients relapse, we will note them as relapsed and exclude them from the 
overall data. The number of patients lost to follow-up will be noted in the study results. In 
recruitment, we will aim to have subjects in excess so that if patients are lost we can still 
have sufficient participants.  
Timeline and Resources 
 Investigators will break the study down into four phases: an experimental outline 
must be written and submitted and approved by the BUMC IRB, a three-month 
recruitment phase, a six-month experimental phase, and an analysis phase. Recruitment 
will take place Monday through Friday for three months at five methadone clinics in the 
city of Boston. If investigators are unable to recruit the adequate number of patients for 
the study, the recruitment phase may be extended. The experimental stage will take a 




 For this study to occur, investigators will need significant funding at each of the 
methadone clinics. Five MAs need to be accounted for to handle the initial screening and 
collection of urine samples over the recruitment and experimental stages. The recruitment 
and experimental stages should take nine months. Similarly, two social workers per 
methadone clinic should be present throughout the duration of the experimental stage, 
nine months. For each patient, $25 Visa ClinCard should be allocated for initial screening 
and for each subsequent MI session. 
Institutional Review Board Statement 
 The study principal investigator supervisor will submit a detailed outline of this 
study to the BU IRB via BU’s Integrated Network for Subject Protection in Research 
(INSPIR) software. Investigators will file the study under expedited review status under 
category three due to the investigators procurement of urine in a non-invasive fashion. 
Investigators will also file under category seven – use of psychiatric interviews.  
 Under BUMC IRB guidelines, a separate IRB does not need to be filed with non-
BU facilities if study staff are BU affiliated.  
 The study will include research on individual characteristics, behavior and the 
subjects will be interviewed. This will not be a clinical investigation of a drug, device, or 
other product regulated by the Food and Drug Administration (FDA).  
All study personnel in direct contact with study subjects will complete human 
subject’s protection training per BUMC protocol. Non-BUMC affiliated study personnel 




BUMC protocol. Unanticipated problems, adverse events, protocol deviations will be 
reported to the IRB as required by BU IRB protocol. 
CHAPTER 4 
 Conclusion 
Previous studies have found psychosocial interventions along with opioid receptor 
therapies like methadone and buprenorphine to be effective in treating OUD.94 Despite 
the effective treatment, OUD persists and is a major public health issue and has become 
more prevalent in the recent past.  
Prior studies identify housing status as a significant social co-morbidity but few 
studies have addressed it as part of a treatment regimen for OUD. Among the studies that 
have addressed housing with OUD, none used patients actively receiving methadone in 
an observational study. The study aims to capture patients already living in stable housing 
rather than providing new housing as a way to save costs.   
The study principally compares the ratio of patients suffering from opioid use 
disorder that relapse at one-, three- and six- month time points.  Patients will be separated 
into four populations receiving the same standard care of treatment, MMT + MI. 
Secondary outcomes will be measuring a difference in the mean time to relapse between 
the populations. At the conclusion of the study, patient housing status will be compared 
to see if stable housing is associated with reduced frequency of relapse and longer time to 
relapse. 
 Sourcing patients from five Boston area methadone clinics will provide a large 




allow investigators to have patients from a diversity of backgrounds, races, and cultures. 
The population of Boston still may not be generalizable to all of the United States.  
The study design was intended to be as generalizable as possible and will include 
minors with parent or guardian permission, adults, patients with psychiatric comorbidities 
and pregnant patients. This study will include all patients receiving methadone and not 
using other opioid agonist therapies. This study in its design aims to minimize exclusions. 
Maximizing inclusion criteria makes the data generalizable and applicable to a wide 
variety of patients but may dampen the effect in a population that sees greater benefit to 
stable housing may be cancelled by a population that is not affected as much by stable 
housing. 
Prospective observational cohort studies are inherently limited due to their lack of 
randomization and potential for confounding. A significant barrier for homeless patients 
is public transportation and the availability of public health programs like shelter or 
health insurance. Fortunately, in Massachusetts, methadone is covered by MassHealth. 
Availability of free methadone is not a guarantee throughout most of the United States. 
Public transportation like subways makes traveling to methadone appointments easier in 
Boston because of its robust network of trains.  
 This study will likely see a significant drop-out of patients. It will be difficult to 
follow up with patients should they decide to drop out of the study. In the proposed study 
design, patients who drop out for any reason will be excluded. Patients may decide to not 




more patients in an attempt to keep the necessary sample size for statistical analysis. The 
total number of relapse patients will be noted and listed as a caveat.  
 Patients regardless of their methadone use history or length of substance 
dependence will also be included. We chose to include patients regardless of their last 
relapse time to make the study more generalizable to the OUD population as a whole. As 
a result, the study may include patients who have been on methadone for a prolonged 
period of time. A 2016 Canadian study of 250 patients on MMT showed a mean relapse 
time of 99.04 days (74.4).115 Prolonged times of methadone use may suggest the patients 
are stable and less likely to relapse.  
Investigators will exclude only patients taking opioid receptor agonists for chronic 
pain control. This decision was made because opioid pain control plus opioid 
maintenance therapy would confound the study. 
Due to the study design of including patients with psychiatric comorbidities, 
patients may be prescribed substances that will be positive on the expanded urine 
toxicology, benzodiazepines for example. These patients will not be marked for relapse 
because they are prescribed medications for medical need. Similarly, patients that self-
prescribe marijuana will not be marked as substance users or relapse should they decide 
to use.  
 
Summary 
 OUD is a chronic relapsing illness associated with significant medical and social 




Opioid receptor modulators, such as naltrexone, methadone, and buprenorphine, 
have been well studied and are effective at treating OUD.18 Today, the standard of care in 
the treatment of OUD is a psychosocial intervention plus an opioid receptor modulator. 
Despite the existence of effective treatment, OUD has persisted. 
Over the past 20 years, deaths from complications of OUD including overdose 
have increased nearly 20-fold (Figure 1). OUD prevalence has reached epidemic levels. 
Prescription opioids are the primary driver of opioid-related fatalities.4 The rise of OUD 
is multi-factorial. Opioid approaches to pain control, limited drug treatments, and eroding 
economic opportunities have contributed to the epidemic.5. Overdoses from fentanyl and 
heroin combinations increased by 88% per year from 2013 to 2016.9 
A 2016 systematic review by Dugosh et al found psychosocial interventions 
combined with MMT or buprenorphine to be effective in the treatment of OUD. Few 
studies have evaluated the efficacy of one psychosocial intervention over another. A 2012 
study by Tuten et al found that abstinent contingent recovery housing improves 
abstinence in opioid dependent patients and that the addition of reinforcement-based 
treatment counselling further improved abstinence. A 2018 prospective cohort study by 
Wooditch et al. found that regulated housing and sober-living environments were 
associated with lower illicit substance use.  
 Building on the findings of Dugosh, Tuten and Wooditch, a prospective cohort 
study is planned exploring the effects of stable housing among patients who receive the 
current standard of care, MMT plus MI. Thus far, there has not been a study on patients 




positively influence abstinence times but their study used patients who were not receiving 
MMT or Suboxone. The proposed study is innovative by including patients who receive 
the MMT, buprenorphine, and stable housing as a way to improve abstinence times.   
Clinical and/or Public Health Significance 
Upon conclusion and analysis of the study data, we expect investigators to find 
stable housing to have a positive influence on abstinence times in patients receiving the 
standard of care treatment for OUD. This study is of particular interest due to prevalence 
of OUD and its intransigence to treatment.  
We hope to include stable housing as part of a treatment regimen for patients 
suffering from OUD.  
Positive findings could be used to influence U.S. federal and state legislation to 
provide additional resources for patients struggling with OUD and homelessness. 
Additionally, future randomized controlled trials studying OUD with MMT + MI and 











Appendix 1: Opiate Use Disorder DSM-V Criteria 
The severity of OUD is graded on the number of positive symptoms listed below: 
A. Mild OUD – 2-3 items. 
B. Moderate OUD – 4-5 items.  
C. Severe OUD – 6+ items over 12 months.27 
The severity of OUD influences treatment modality. 
1. Opioids are often taken in larger amounts or over a longer period of time than 
intended. 
2. There is a persistent desire or unsuccessful effort to cut down or control opioid 
use. 
3. A great deal of time is spent in activities necessary to obtain the opioid, use of 
the opioid, or recover from its effects. 
4. Craving, or a strong desire to use opioids.   
5. Recurrent opioid use resulting in failure to fulfill major role obligations at 
work, school, or home. 
6. Continued opioid use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of opioids. 
7. Important social, occupational or recreational activities are given up or reduced 
because of opioid use. 




9. Continued use despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by opioids. 
10. Tolerance as defined by either of the following: 
  A. A need for markedly increased amounts of opioids to achieve 
intoxication or desired effect. 
  B. Markedly diminished effect with continued use of the same amount of 
an opioid. 
11. Withdrawal as manifested by either of the following: 
  A. The characteristic opioid withdrawal syndrome. 





Appendix 2: Non-Pharmacological Treatments for Neonatal Abstinence Syndrome 
• Non-Pharamacological Treatments for Neonatal Abstinence Syndrome as adapted from 
Velez and Jansson, 2008106Irritable infants may be soothed with gentle rocking. 
• Frequent small feedings. Breast feeding is encouraged but only in if the mother meets the 
following criteria:  
o Mothers must be able to provide consent to discuss treatment progress with a substance 
use disorder treatment counsellor 
o Mothers must plan to continue SUD treatment postpartum 
o Mothers must be abstinent from illicit substances for greater than 90 days prior to 
beginning breast feeding.  
o Mothers must have a negative urine toxicology at delivery 
o Mothers have received consistent prenatal care 
o Mothers should have no medical contraindication to breast feeding 
o Mothers should not be taking a medication that is contraindicated during lactation. 
• Pacifiers may be beneficial to calm down oral hypersensitivity.  
• Maternal education on soothing her irritated infant is beneficial in promoting dyadic 
synchrony. 
• Rooming-in (ie, placing the mother and infant in the same room) 









Appendix 4: Motivational Interviewing Tenets 
Motivational Interviewing spirit rests on four key tenets:77 
 A. Collaboration between practitioner and the patient in contrast to assuming the 
role of a treatment expert and confronting the patient.77 
 B. Compassion – in MI aims to better understand how the patient feels and to 
promote what is in the best interest of the patient.77  
 C. Autonomy – MI recognizes that making the choice to change is up to the 
patient.77 
 D. Evocation or drawing out the client’s ideas about change rather than inserting 
the practitioner's ideas and opinions. The practitioner must work on drawing out the 
patient’s motivations rather than to follow the practitioner’s opinion.77 
 
Motivational Interviewing rests on four key skills, explained by OARS: 
 O – Open questions that encourage further elaboration and consideration. 
 A – Affirmations that foster positive feelings in the consultation. 
 R – Reflections that indicate that the clinician has heard and accurately 
understood the patient. 
 S – Summaries that extend the basic reflections to include a sense of momentum 
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